The study reveals that glutamine supplementation within the tumor milieu augments cDC1-mediated CD8+ T cell immunity, thereby inhibiting tumor growth and overcoming resistance to immune checkpoint blockade therapies​​. The gene discussed is CD8A; the disease is neoplasm.